Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

52.41
+0.37000.71%
Volume:306.73K
Turnover:16.03M
Market Cap:4.94B
PE:-110.00
High:52.71
Open:52.07
Low:51.63
Close:52.04
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.29
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:201.46
PE(LYR):-183.03

Loading ...

Travere Therapeutics names Jula Inrig EVP, head of R&D, as CRO William Rote plans 2027 retirement

Reuters
·
Jun 17

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

THOMSON REUTERS
·
Jun 17

Travere Therapeutics (TVTX) Stock After First Non GAAP Profit And Positive FILSPARI Data Is Valuation Up To Date

Simply Wall St.
·
Jun 14

Travere Therapeutics, Inc. : Wells Fargo Raises Target Price to $65 From $50

THOMSON REUTERS
·
Jun 12

Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo

TIPRANKS
·
Jun 12

Travere Therapeutics grants 32,000 inducement RSUs to six new employees

Reuters
·
Jun 12

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 12

3 Stocks That May Be Priced Below Their Estimated Value In June 2026

Simply Wall St.
·
Jun 09

A Look At Travere Therapeutics (TVTX) Valuation After New Long Term FILSPARI FSGS Data

Simply Wall St.
·
Jun 07

Travere Therapeutics says Filspari generally well tolerated in Phase 3 study

TIPRANKS
·
Jun 04

Travere reports 5-year DUPLEX extension data showing sustained proteinuria reduction with FILSPARI in FSGS

Reuters
·
Jun 04

Travere Therapeutics Presents Long-Term Open-Label Extension Data From the Phase 3 Duplex Study at the 63Rd European Renal Association (Era) 2026 Congress

THOMSON REUTERS
·
Jun 04

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (ELAN), AbSci (ABSI) and Travere Therapeutics (TVTX)

TIPRANKS
·
Jun 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Picard Medical, Inc. (PMI) and Travere Therapeutics (TVTX)

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Reuters
·
Jun 02

Travere Therapeutics enters into exclusive licensing agreement with Everest

TIPRANKS
·
Jun 02

Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines

MT Newswires Live
·
Jun 02

Travere Therapeutics licenses Everest Medicines’ civorebrutinib outside China in USD 112.5 million deal

Reuters
·
Jun 02

Travere Therapeutics - to Pay Tiered Royalties on Future Civorebrutinib Sales

THOMSON REUTERS
·
Jun 02